Clinical trials: Urethral Diseases
Prostate Cancer
Performance Evaluation of the AMS CONTINUUM™ Device
1. To assess the safety of using the CONTINUUM™ device by monitoring the side effects and complications associated with the Device following a radical prostatectomy. 2.
- Trial name
- NCT00894933
- Testing
- CONTINUUM™
- Where
- 6 sites in United States
- Volunteers
- 33 people
- Sponsor
- American Medical Systems
Lower Urinary Tract Symptoms, Bladder Outlet Obstruction
A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
This study examined the safety, tolerability, and efficacy of mirabegron (YM178) compared to placebo.
- Trial name
- NCT00410514
- Testing
- Mirabegron
- Where
- 27 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Astellas Pharma Inc
Urothelial Carcinoma
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
The main purpose of this study is to evaluate the safety and efficacy of the study drug ramucirumab in combination with docetaxel in participants with urothelial cancer who failed prior platinum-based therapy.
- Trial name
- RANGE (NCT02426125)
- Testing
- Ramucirumab, Docetaxel
- Where
- 141 sites in United States, Australia and 21 more
- Volunteers
- 530 people
- Sponsor
- Eli Lilly and Company
Bladder Cancer
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
The purpose of this study is to determine whether Patients with Locally Advanced or Metastatic Bladder Cancer who receive Eribulin Mesylate Administered in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus…
- Trial name
- NCT01126749
- Testing
- Gemcitabine, E7389, Cisplatin
- Where
- 42 sites in United States, Germany and 4 more
- Volunteers
- 92 people
- Sponsor
- Eisai Inc.
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic…
- Conditions
- Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell
- Trial name
- NCT02443324
- Testing
- Ramucirumab, Pembrolizumab
- Where
- 22 sites in United States, France and 4 more
- Volunteers
- 175 people
- Sponsor
- Eli Lilly and Company
Bladder Cancer, Transitional Cell Bladder Cancer
A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth)…
- Conditions
- Bladder Cancer, Transitional Cell Bladder Cancer, Urethra Cancer, Ureter Cancer
- Trial name
- NCT00661609
- Testing
- AZD4877
- Where
- 36 sites in United States, Canada and 3 more
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Transitional Cell Carcinoma of Bladder, Urethra Cancer
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-801 in a biochemotherapy regimen either containing cisplatin and gemcitabine or containing gemcitabine alone in patients who…
- Conditions
- Transitional Cell Carcinoma of Bladder, Urethra Cancer, Ureter Cancer, Malignant Tumor of Renal Pelvis
- Trial name
- NCT01326871
- Testing
- Cisplatin, Gemcitabine, ALT-801
- Where
- 16 sites in United States
- Volunteers
- 68 people
- Sponsor
- Altor BioScience
Acute Urinary Retention, Benign Prostatic Hyperplasia
Prostatic Urethral Lift in Subject With Acute Urinary Retention
Assess feasibility and safety of the Prostatic Urethra Lift (PUL) procedure in patients with acute urinary retention secondary to benign prostatic hyperplasia (BPH).
- Trial name
- NCT03194737
- Testing
- UroLift System Procedure
- Where
- 6 sites in United Kingdom
- Volunteers
- 101 people
- Sponsor
- NeoTract, Inc.
Bladder Outlet Obstruction, Lower Urinary Tract Symptoms
The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects
Crossover comparison of different flow meters with a digital home flow meter as a reference. Main hypothesis: Reapeated home flow measurements with a disposable device will provide a better understanding of the patients urinary…
- Trial name
- NCT00710749
- Testing
- Disposable device, Digital device, Clinic flow measurement
- Where
- 4 sites in United States, Netherlands and 2 more
- Volunteers
- 60 people
- Sponsor
- Wellspect HealthCare
BPH With Symptomatic Lower Urinary Tract Symptoms
ProVee Urethral Expander System IDE Study (ProVIDE)
A study to evaluate the safety, performance, and effectiveness of the ProVee Urethral Expander System (Investigational Device) when used in subjects with symptomatic urinary obstruction related to benign prostatic hyperplasia…
- Trial name
- ProVIDE (NCT05186740)
- Testing
- ProVee Urethral Expander System, Urethral Access Sheath
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- ProVerum Medical
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
This is a study that will test how an experimental drug (enfortumab vedotin) affects patients with cancer of the urinary system (urothelial cancer).
- Conditions
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms
- Trial name
- EV-201 (NCT03219333)
- Testing
- Enfortumab vedotin
- Where
- 81 sites in United States, France and 6 more
- Volunteers
- 219 people
- Sponsor
- Astellas Pharma Inc
Carcinoma of Urinary Tract, Urethral Carcinoma
Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
This multicenter trial will enroll participants with metastatic transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis who have had disease progression on first-line platinum-based chemotherapy regimens.
- Conditions
- Carcinoma of Urinary Tract, Urethral Carcinoma, Carcinoma of Ureter, Carcinoma of Renal Pelvis
- Trial name
- NCT01282463
- Testing
- Docetaxel, Ramucirumab DP, Icrucumab
- Where
- 32 sites in United States, Canada
- Volunteers
- 148 people
- Sponsor
- Eli Lilly and Company
Stress Urinary Incontinence
Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients
The hypothesis under evaluation is that fesotorodine may provide clinical benefit in the treatment of the condition of stress urinary incontinence
- Trial name
- NCT01042236
- Testing
- Fesoterodine
- Where
- Denmark
- Volunteers
- 22 people
- Sponsor
- Pfizer
Stricture Urethra
ROBUST I Pilot Study, Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease
Robust I study is a feasibility study for evaluating the safety and efficacy of DCB.
- Trial name
- ROBUST (NCT03014726)
- Testing
- Urotronic Drug Coated Balloon (DCB)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Urotronic Inc.
Prostate Cancer
Global Performance Evaluation of the AMS CONTINUUM™ Device
1. To evaluate Device performance in providing mucosa to mucosa apposition to facilitate sustainable vesico-urethral anastomosis during a radical prostatectomy procedure. 2.
- Trial name
- NCT01083199
- Testing
- CONTINUUM™
- Where
- 2 sites in Greece, Spain
- Volunteers
- 10 people
- Sponsor
- American Medical Systems
Urothelial Carcinoma
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
This study was conducted to examine survival, disease-free survival, safety, and the magnitude of the immune response induced following administration of DN24-02 in subjects with HER2+ urothelial carcinoma.
- Trial name
- NCT01353222
- Testing
- DN24-02, Standard of Care
- Where
- 60 sites in United States
- Volunteers
- 142 people
- Sponsor
- Dendreon
Urethral Stricture
ROBUST III- Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease
ROBUST III is a prospective, multi-center, randomized controlled adaptive sample size clinical trial to establish the safety and effectiveness for the Optilume Stricture Drug Coated Balloon (DCB).
- Trial name
- ROBUST-III (NCT03499964)
- Testing
- Optilume Drug Coated Balloon (DCB), Control Treatment
- Where
- 22 sites in United States, Canada
- Volunteers
- 127 people
- Sponsor
- Urotronic Inc.
Bladder Cancer, Urothelial Carcinoma
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
The purpose of the ATLAS study is to determine how patients with locally advanced unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Renal Pelvis Carcinoma
- Trial name
- ATLAS (NCT03397394)
- Testing
- Rucaparib
- Where
- 64 sites in United States, France and 4 more
- Volunteers
- 97 people
- Sponsor
- pharmaand GmbH
Catheterization
Study of a Urethral Catheter Coated With Eluting Silver Salts (SUCCESS)
Urinary catheters are often needed in hospital patients, but their use can increase the chance that a catheter associated urinary tract infection (called a CAUTI) may occur.
- Trial name
- SUCCESS (NCT00482547)
- Testing
- Hydrogel Silver Salts Coated Latex Urinary Catheter System, Bard silicone elastomer coated latex catheter system
- Where
- United States
- Volunteers
- 1,188 people
- Sponsor
- C. R. Bard